水飞蓟素胶囊治疗2型糖尿病肾病的临床观察  

Renoprotective effect of Silymarin capsules on type 2 diabetic nephropathy

作　　者：万青松[1] 谢红萍[1] 杨波[1] 欧继红[1] 

机构地区：[1]南华大学附属第一医院肾内科,湖南衡阳421001

出　　处：《中国现代医学杂志》2015年第24期103-105,共3页China Journal of Modern Medicine

摘　　要：目的探讨水飞蓟素治疗2型糖尿病肾病(DN)的疗效及作用机制。方法 40例2型DN患者,在前期服用降压药基础,包括最大推荐剂量血管紧张素转化酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB),随机平均分为水飞蓟素组和安慰剂组,分别予水飞蓟素胶囊及安慰剂治疗,实验前后测量患者尿丙二醛(MDA)、尿肿瘤坏死因子α(TNF-α)、尿白蛋白肌酐比(UACR)及生化指标。结果 12周后,两组患者UACR均下降,与安慰剂组相比,水飞蓟素组UACR下降更显著;与安慰剂组对比,水飞蓟素组尿TNF-α、MDA下降更显著。结论水飞蓟素胶囊可以通过抑制MDA、TNF-α降低2型糖尿病肾病UACR而作为治疗糖尿病肾病新的药物。【Objective】 To investigate the effect and the mechanism of Silymarin on type 2 diabetic nephropathy. 【Methods】 In addition to ongoing antihypertentive treatment including maximally recommended doses of an ACE inhibitor or an ARB, forty type 2 diabetic patients with nephropathy were devided into Silymarin group and placebo group, which were treated with Silymarin capsules and matched placebo respectively.Urinary levels of tumor necrosis factor（TNF-α）, malondialdehyde（MDA）, urinary albumin-creatinine ratio（UACR） and other biochemical parameters were measured from baseline to the end of the treatment phase.【Results】 After twelve weeks, although UACR decreased in both groups, this decrement was significantly more obvious in the Silymarin group than that in the placebo group. Urinary levels of TNF-α and MDA also decreased significantly in the Silymarin compared with the placebo group. 【Conclusions】 Silymarin capsules reduce UACR by inhibiting MDA and TNF-α and may be considered as a novel drug for patients with diabetic nephropaty.

关 键 词：水飞蓟素 尿病肾病 二醛 瘤坏死因子α 尿白蛋白肌酐比 

分 类 号：R587.1[医药卫生—内分泌]